Supplementary Information

Immune evasion of *Borrelia miyamotoi*: CbiA, a novel outer surface protein exhibiting complement binding and inactivating properties

Florian Röttgerding¹, Alex Wagemakers^{2†}, Joris Koetsveld^{2†}, Volker Fingerle³, Michael Kirschfink⁴, Joppe W. Hovius², Peter F. Zipfel^{5,6}, Reinhard Wallich⁴, and Peter Kraiczy^{1*}

¹Institute of Medical Microbiology and Infection Control, University Hospital of Frankfurt, Frankfurt, Germany
²Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands
³National Reference Center for Borrelia, Oberschleißheim, Germany
⁴Institute of Immunology, University of Heidelberg, Heidelberg, Germany
⁵Institute of Immunology, University of Heidelberg, Heidelberg, Germany
⁶Friedrich Schiller University, Jena, Germany

† A.W. and J.K. contributed equally to this study

Corresponding author: Dr. Peter Kraiczy, Institute of Medical Microbiology and Infection Control, University Hospital of Frankfurt, Paul-Ehrlich-Str. 40, D-60596 Frankfurt, Germany, Phone: +49-69-6301-7165, E-mail: Kraiczy@em.uni-frankfurt.de

		20		40		
CbiA	MHYIKKYLLF	ILLL-NLINC	NLFNKNKNLD	, HNLQPNKINN	IISSLDSNQK	49
BhCRASP-1	MQLTKKYLPA	ILLLLSLASC	DLFYKNRNSN	ANL	- L K T L D N N Q K	42
BpcA	MK KKCLLT	ILLL-SLVNC	GLLSKNKNSE	TSL	- LNTLDNNQK	39
HcpA	M RLYLS	MALLLSIIGC	ELLSKNAN	LQPKTLET	LESNIDDGQK	42
BtcA	MK KKCLLT	IILL-SLVSC	GLSSKNKNSE	TSLL-NIETN	LLNTLDDNQK	46
	60 I		80 I		100 I	
CbiA	QALISFKNLV	NNKQYSKDLE	QASKSYLEDL	KKNNQDLNLQ	NKLNQELNCD	99
BhCRASP-1	QALIYFKDTL	QDKKYLSYLT	TSQKNFLDDL	EKNKKAPGLQ	YKLKKTLSSE	92
BpcA	QALITFKDLL	QDKNHRSILE	KQQKSILKDL	EKHQENSNLQ	DKLKKTLNSE	89
HcpA	QALAFFQESL	QDNKHLDALK	QAQSALLKDI	К	DKPQKTLNFK	83
BtcA	QALITFKDLL	QDKKHLSILE	KQQKSILEDL	KANQKNYNLQ	DKLKKTLNSE	96
		120		140		
		I		*		
CbiA	YDDSKIEKLF	AQLGNDKMKK	FLQQLHLMLK	SINDGTLISF	SSSNFRDTT -	148
BhCRASP-1	YDESQFNKLL	NELGNAKAKQ	FLQQLHIMLQ	SIKDGTLTSF	SSANFNDL - Q	141
BpcA	YDKTQLNKLF	DELGNIKTKQ	FLQKLHIMLK	SINNGTLTSF	SSSNFKDSNQ	139
HcpA	YNKTKLEQLF	RKLGNDKTKQ	FLKNLHVTIK	FINNGSFQSF	SSANFNDLD -	132
BtcA	YDKNQLNKLF	DELGNIKTKQ	FLQQLHIILQ	SIKDGKPTNF	ASSNFNNLNQ	146
	160 I		180 I			
CbiA	TLSQKKERAL	EYIKRQLYIE	FYFHSNDISD	TEFFFQRTIK	LLETQS 194	
BhCRASP-1	NLEQKKERAL	QSINGELYVE	YYFYINGISN	PDNFFEKIMQ	NLKT 185	
BpcA	TLEQKKEQAL	QYIKGQLYTD	YYLYINGIQD	ANYFFERIMS	VLEI 183	
LlanA						
ПСРА	TLEKKQERAI	NSIKEELYVN	YYLYTNELVD	LDYFFYRAMN	YLS 175	
BtcA	TLEKKQERA I TLEQKKEQAL	NSIKEELYVN KYIKDKLYTD	YYLYTNELVD YYLYINGIQD	LDYFFYRAMN ANYFFERIMS	YLS 175 LLES 190	

Alignment of proteins of relapsing fever spirochetes. Deduced amino acid sequences of CbiA, BhCRASP-1, BpcA, HcpA, and BtcA were aligned using CLC Sequence Viewer, Version 7.7 (Qiagen, Aarhus). Conserved residues are highlighted in light grey and the proposed FH-binding region derived from BhCRASP-1 is underlined. Asterisk indicates the introduced stop codon at position 133 to generate mutant CbiA₂₀₋₁₃₂ lacking 62 aa at the C-terminus.

0.85

80 100 Position



The predicted probability of α -helices and coiled coils structures within CbiA was assessed using ProtScale and COILS (<u>www.expasys.org</u>). COILS was performed with (2.5) and without weighting by using a 14-, 21-, and 28-amino-acid window.

40 60

120 140 160 180



Alternative pathway

Complement inhibition of borrelial proteins on the alternative pathway. The inhibitory capacity of borrelial proteins on the alternative pathway was analyzed by Wielisa® (Euro Diagnostica, Malmö, Sweden). NHS diluted 1:18 was pre-incubated with increasing concentrations (6, 12, 18 μ g/ml each) of borrelial proteins or BSA (negative control) and then added to microtiter plates coated with LPS. Following incubation, C5b-9 deposition was measured using an anti-C5b-9 mAb at 405 nm. Means from three independent experiments are shown and error bars correspond to SD. Raw data were analyzed using one-way ANOVA with post hoc Bonferroni correction. ***, *P* = .001, **, *P* = .05.

Uncropped gel and Western blots of figure 1



anti-FH

Panel 1E



Full-length Western blots of figure 2

kDa	6380 NC	cibiA	kDa	C36C KC	BPCA	BicA	kDa	HCPA	cspA	BGAT	BSA	
150 - 100 - 75 -			150 - 100 - 75 -				150 - 100 - 75 -					– α-chain (105 kDa) -⊏ ^β -chain (75 kDa) α΄-68 kDa fragme
50 - 37 -	-		50 - 37 -	-	-		50 - 37 -					∽α΄,-43 kDa fragmer ∽α΄-41 kDa fragmer
25 - 20 - 10 -			25 - 20 - 10 -				25 - 10 -					
C3b FI FH	+ + + + - + + - - + - +	+ + + + + - + - +	C3b Fl FH	+ + + + - + + - - + - +	+ + + + + - + - +	+ + + + + - + - +	C3b Fl FH	+ + + + + - + - +	$ \begin{array}{cccc} + & + & + \\ + & + & - \\ + & - & + \\ \end{array} $	+ + + + + - + - +	+ + + + + - + - +	

Full-length Western blot of figure 5, panel B



Full-length Western blots of figure 6, panel D



Full-length Western blots of figure 7, panel B

number of passages	number of passages
kDa 6 11 21 31 41 51 70 - 55 - - FlaB	kDa 6 11 21 31 41 51 70 - 55 -
35 -	35 -
25 -	25 -
15 -	15 -
10 -	10 -

Full-length Western blot of figure 8



Oligonucleotide	Sequence (5'-3') ^a	Use in this work			
chiA F00	ATCTCAATATGCACTATATTTC	Cloning of <i>chiA</i>			
cbiA R0	CTGCAGTATCGATTTATATGTACTCTTC	Cloning of <i>cbiA</i>			
cbiA Bam	CTATTATTAAACCTTATC <u>GGATCC</u> AATTTATTC	Cloning of <i>cbiA</i> in pQE-30 Xa; generation of His-tagged protein			
cbiA Bam	CGAA <u>GGATCC</u> ATGCACTATATTAAAAAATATC	Cloning of <i>cbiA</i> in pBSVA			
cbiA Sph	CGTTT <u>GCATGC</u> ACTCTTTCTCAGAAG	Cloning of <i>cbiA</i> in pBSVA			
BtBam	GTCTTGTTGGATCCGGTTTATCAAG	Cloning of <i>btcA</i> in pQE-30 Xa;			
BtSal	TAT <u>GTCGAC</u> TTAACTTTCTAAAAGTG	generation of His-tagged protein			
glpQ FW	TCATGCTTTAAACAAGAAATG	qRT-PCR of <i>glpQ</i>			
glpQ RV	TCTAGCTCGATTGGGAAATAATTG	qRT-PCR of $glpQ$			
cbiA FW	AGAGCAAGCAAGCAAAAGTT	qRT-PCR of <i>cbiA</i>			
cbiA RV	AAGCTTATAAGTGTGCCGTCATT	qRT-PCR of <i>cbiA</i>			

Supplementary Table S1. Oligonucleotides used in this study

^a, Sequences of specific restriction endonuclease recognition sites are underlined.